InvestorsHub Logo
Followers 58
Posts 10147
Boards Moderated 1
Alias Born 09/21/2016

Re: XenaLives post# 450291

Wednesday, 01/31/2024 11:51:11 AM

Wednesday, January 31, 2024 11:51:11 AM

Post# of 462342
XenaLives

I'd rather see AVXL as a dominant entity in drugs that treat CNS and other disease on a molecular level.

...


OK w/me....BUT ...but (in my VERY LIMITED thinking) AVXL is leading an awakening-discovery process in CNS BIO-Med diseases causal links. I am not Bio-qualified to define/describe the discovery process but I have seen such in my past in semiconductor device physics development physics-engineering. In fact after 40+ years that learning process is still evolving. IMO, the same principals or /+/- new learning apply here also. The big difference is semiconductors present a harder science (trial-error certainty) vs medical-bio learning fields of unknown-unproven variables. FDA needs to refine that model and help everyone to move on for the sake of humanity, IMO.

I do agree that AVXL is presenting the brightest CNS diseases light (by far) .
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News